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Abstract: There have been major changes since the incidents of leukemia development in X-SCID patients after the 
treatments using retroviral gene therapy. Due to the risk of oncogenesis caused by retroviral insertional activation of host 
genes, most of the efforts focused on the lentiviral therapies. However, a relative clonal dominance was detected in a pa-
tient with -thalassemia Major, two years after the subject received genetically modified hematopoietic stem cells using 
lentiviral vectors. This disappointing result of the recent clinical trial using lentiviral vector tells us that the current and 
most advanced vector systems does not have enough safety. In this review, various safety features that have been tried for 
the retroviral gene therapy are introduced and the possible new ways of improvements are discussed. Additional feature of 
chromatin insulators, co-transduction of a suicidal gene under the control of an inducible promoter, conditional expression 
of the transgene only in appropriate target cells, targeted transduction, cell type-specific expression, targeted local admini-
stration, splitting of the viral genome, and site specific insertion of retroviral vector are discussed here. 
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INTRODUCTION 
  Retroviral vectors have been the most preferred gene 
transfer systems in clinical gene therapy until the incident of 
a human trial for the X-linked severe combined immunodefi-
ciency (SCID) [1-3]. The potential risk of insertional onco-
genesis was realized in the trial, infants with X-SCID were 
cured by retrovirus-mediated ex-vivo gene transfer, and the 
trial was credited as the first unequivocal success for gene 
therapy [4]. However, four out of nine successfully treated 
patients later developed leukemia, and it is generally be-
lieved that leukemeogenesis was triggered by unexpected 
activation of a cellular proto-oncogene as a result of retrovi-
ral integration. Since our last review about the safety issues 
related to the use of retroviral vectors in human clinical tri-
als, additional leukemeogenesis were reported [5-7]. It is 
time to re-evaluate all the safety issues concerning the use of 
retroviral vectors. 
  Stable incorporation of retroviral viral DNA into the host 
genome is in itself advantageous, as long-term expression of 
the transgene is possible for achieving therapeutic efficacy. 
However, a non-specific incorporation of viral DNA 
throughout the host genome can either cause a disruption of 
a host gene at the site of incorporation or cause an abnormal 
expression of nearby host genes driven by the enhancer of 
the inserted viral DNA. An insertional interference occurs 
against a host gene involved in a critical cellular function 
such as cell cycle progression, can become a major cause of 
cell transformation and oncogenesis, especially in the pres-
ence of additional physiological or genetic insults. 
  In addition to the risk of insertional mutagenesis, another 
safety issue with the retroviral vector is the possibility of   
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generating replication competent retroviruses (RCR). Al-
though new generations of retroviral vectors are designed to 
reduce the production of RCR, additional efforts are required 
to ensure the complete elimination of the problem. 
  Recently developed lentiviral gene transfer systems share 
many features of the retroviral systems. The viral genome 
integrates into host chromosomes, and inserted genes are 
maintained in the cells permanently. In contrast to conven-
tional retroviral vectors, which require cell division for infec-
tion, lentiviral vectors infect efficiently non-dividing cells as 
well as dividing cells. Therefore, lentiviral vectors can be 
applied for transgene expression in neuronal cells. Most of 
the lentiviral vectors used in gene therapy are based on the 
human immunodeficiency virus (HIV). The major limitations 
of using HIV-originated lentiviral vectors in clinical trial are 
the safety concerns related to their HIV origin. Recent trials 
of lentiviral vector systems will be described in relevant 
chapters. 
  In this review, we will discuss about safety issues relat-
ing to the use of retroviral vectors for the therapeutic gene 
delivery. Suggestions for the possible solutions to these is-
sues and future directions for an overall increase in the safety 
and efficiency of retroviral gene therapy protocols will be 
provided. Other important parameters in cell-based ex-vivo 
retroviral gene therapy protocols are already covered else-
where [8], including cell type and numbers, observation pe-
riod, proliferation capacity, age of patients, immunity, and 
side effects of transgene expression. 
TARGETED RETROVIRAL TRANSDUCTION 
  Current retroviral transfer system lacks specificity for 
target cell types. Non-specific infection hinders the applica-
tion of retroviral system for the gene
  transfer to particular 
cell types in a mixed cell population. Tissue targeting
  is 
highly desirable and is expected to be valuable for various in 
vivo gene therapy
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  Infection of target cells by retroviruses is initiated by 
binding of the viral envelope protein to cell surface receptors 
[10]. Infusion of viral and cellular membranes leads to the 
internalization of the viral core [11]. In the past years, vari-
ous retrovirus receptors, coreceptors and cofactors have been 
identified and studied for their role in viral entry [12], and 
attempts have been made to engineer viral envelope proteins 
and cellular receptors for attaining changes in the viral tro-
pism [13, 14]. 
  In an approach for a targeted transduction, envelope pro-
tein modification by attaching a peptide ligand such as epi-
dermal growth factor (EGF) receptor binding domain to the 
NH2-terminus of the envelope glycoprotein (SU) was at-
tempted [15-17]. Incorporation of the chimeric envelope 
protein into the viral particle allows binding of retrovirus to 
the receptor-positive target cells. The subsequent viral entry 
steps are blocked, however, because EGF receptors do not 
support these processes. As a protease cleavable linker was 
used in this chimeric protein to join the peptide ligand and 
SU, an appropriate cellular protease can cleave the attached 
ligand. Factor Xa [18, 19], plasmin [17], matrix-metallo-
proteases (MMPs) [16], or intracellular protein convertases 
[20] were used for this purpose. Because overexpression of 
MMPs is frequently associated with angiogenesis, inflamma-
tion, and cancer invasion, MMPs are considered to be inter-
esting targets for the protease-activatable gene delivery sys-
tems. Using MMP-activatable retroviral vectors, selective 
transduction of MMP-rich tumor cells was achieved in a 
heterogeneous cell population, but with somewhat reduced 
efficiency of transduction [17, 21]. Similarly, targeted infec-
tion for the high-molecular-weight melanoma-associated 
antigen (HMWMAA) expressing tumors was achieved by 
fusing a single chain antibody recognizing HMWMAA to 
the amino terminus of the surface domain of MLV with a 
matrix metalloprotease-2 (MMP2) cleavage site linker [22]. 
  Matrix targeting is another approach and matrix-targeted 
retroviral vectors were found to be more efficient than un-
modified vectors [23, 24]. A matrix-targeted retroviral vector 
was constructed by attaching collagen-binding polypeptide 
sequence to the amino-terminal region of the amphotropic 
4070A envelope protein. Because tumor development and 
accompanied angiogenesis is associated with remodeling of 
extracellular matrix components, these vectors accumulate at 
sites of tumor development with newly exposed collagens. 
When the matrix-targeted retroviral vector expressing domi-
nant mutant cyclin G1 was administered by portal vein infu-
sion, vector particles accumulated in the angiogenic tumor 
vasculature within 1 hour of infusion. These vectors, Rexin-
G, transduced tumor cells with high efficiency and reduced 
the volume of tumor [23]. In clinical studies, Rexin-G 
showed significant anti-tumor activities in breast, colon, 
lung, skin, muscle, pancreatic, and bone cancers [25, 26]. 
Rexin-G was granted Orphan Drug Status by the US FDA in 
2008. 
  Targeting retroviral delivery to quiescent interleukin-2 
(IL-2)-dependent cells was also reported [27]. In this report, 
chimeric amphotropic MLV envelope glycoprotein fused 
with IL-2 was used for a direct binding of the viral particles 
to the IL-2 receptors expressed on G0/G1 arrested cells, re-
sulting in a transient stimulation of cell proliferation. Subse-
quent viral entry was mediated by unmodified envelope pro-
teins co-expressed on the same virus particles. A 34-fold 
increase in transduction efficiency was observed with this 
method. Additionally, targeting efforts for T cells [28], and 
other cancer cells [29, 30] were reported. For the specific 
transduction of HIV-envelope expressing cells, envelope 
pseudotyping was used to create hybrid CD4/CXCR4 recep-
tors for MLV retrovirus [31, 32] and lentivirus [31, 32], In 
order to improve transduction efficiency frequently observed 
to be low for the targeted retroviral vectors, binding defec-
tive but fusion competent hemagglutinin (HA) protein has 
also been tried [33]. 
LOCAL DELIVERY 
  If local delivery of retroviral vectors is available for an 
effective treatment of a disease, it will be generally safer 
than systemic delivery in terms of toxicology and long term 
side effects. A number of studies have shown the efficacy 
and safety of locally delivered retroviral vectors. A retroviral 
vector expressing antiproliferative dominant negative mutant 
cyclin G1 (dnG1) was successfully used for the prevention of 
eximer laser-induced corneal haze [34]. Biodistribution study 
after the treatment of surgically induced rabbits with eye 
drops containing dnG1 retroviral vectors showed no evi-
dence of vector dissemination in non-target organs. Local-
ized delivery of lentiviral vectors into the substantia nigra of 
adult rats has also been tried [35]. In a phase I clinical trial 
for direct intratumoral injection of interferon- retroviral 
vectors in advanced melanoma patients, viral injection was 
well tolerated and no toxicity was reported [36]. This sug-
gests that the direct injection approach is feasible for treating 
solid tumors with retroviral vectors. 
  In terms of potential problems associated with concomi-
tant transduction of surrounding non-target cells, ex vivo 
cell-based gene therapy with local delivery can be a better 
choice, if extra time and expenses are tolerated. As an exam-
ple, an ex vivo cell-mediated gene therapy has been per-
formed successfully for the treatment of artificially induced 
hyaline cartilage damage in animals, by injecting TGF-1-
retrovirus transduced fibroblasts into the knee joints [37, 38]. 
Cancer regressions were reported after the transfer of geneti-
cally engineered lymphocytes [39]. Autologous lymphocytes 
from peripheral blood using retroviruses that encode T cell 
receptors to specific tumor-associated antigens were trans-
ferred to patients. Transduced normal peripheral blood cells 
were converted into cells which specifically recognized and 
destroyed cells from corresponding cancers. 
INTEGRATION OF RETROVIRUS INTO THE HOST 
CHROMOSOME 
 In  the  ex-vivo gene therapy trials to treat the rare immune 
deficiency disorder X-SCID, patients were treated with 
autologous hematopoietic stem cells transduced with a re-
combinant retrovirus expressing the common gamma chain 
(c) of interleukin receptor [4]. Although, nine out of eleven 
treated children showed dramatic improvements with almost 
fully restored immune systems, four of the nine cured pa-
tients developed leukemia (T-cell acute lymphoblastic leu-
kemia; T-ALL) between 3 and 6 years after the treatment in 
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intron of the growth-promoting LMO2 gene of the leukemic 
clones in patient 4, and approximately 3 kb upstream of the 
first exon of the same gene in patient 5 [1-3]. In patient 10, 
there was another insertion near the proto-oncogene BMI1 in 
addition to the first insertion near LMO2. In patient 7, blast 
cells showed an insertion near a third proto-oncogene 
CCND2 [40]. Another case of leukemogenesis was reported 
in a separate X-SCID study conducted in United Kingdom 
[6]. In addition to the integration of vector in the upstream of 
LMO2 gene, gain-of-function mutation in NOTCH1, deletion 
of tumor suppressor gene locus cyclin-dependent kinase 2A 
(CDKN2A), and translocation of the TCR-b region to the 
STIL-TAL1 locus were found. Two cases of myelodysplasia 
were reported in a clinical trial for X-linked chronic granu-
lomatous disease (X-CGD) [7]. Both patients showed an 
insertional activation of ecotropic viral integration site 1 
(EVI1) and monosomy 7. LMO2 is a LIM domain transcrip-
tion regulator involved in hematopoiesis [41] and is reported 
to be activated in T cell leukemia by chromosomal transloca-
tion [42]. LMO2 is suggested to reactivate a hematopoietic 
stem cell (HSC) specific transcriptional program [43]. Long-
term thymocyte self-renewal due to the over-expression of 
LMO2 could be the cause of T cell leukemia. The BMI1 
gene was known to regulate stem cell proliferation [44, 45]. 
MMI1 is suspected to contribute the leukemic cell prolifera-
tion with LMO2. Massive and sustained expression of 
CCND2 was detected in the CCND2-rearranged T-ALL, 
compared to the down-regulation during the progression 
from the early stages of normal human T-cell [46]. Over-
expression of CCND2 in one of the patients could be one of 
the oncogenic transition mechanisms to T-ALL. 
  Current U.S. Food and Drug Administration (FDA) per-
spective on X-SCID clinical trials is that gamma-retroviral 
vectors can be used in clinical trials to treat X-SCID under 
the following conditions: when previous hematopoietic stem 
cell/bone marrow transplantation is failed or there is no rea-
sonable alternative therapy [47]. Although, clinical trials are 
allowed to proceed for other clinical indications, investiga-
tors and patients are required to be informed with strong and 
clear communication of risks.  
  The general consensus of the experts of the review 
boards in the US and other countries is that the benefits 
might outweigh the risks in most SCID-related retroviral 
gene therapy trials. In a Recombinant DNA Advisory Com-
mittee (RAC) meeting held on March 14, 2007, it is recom-
mended for all integrating vectors to test for vector se-
quences every 6 months first 5 years and test yearly next ten 
years or until no vector is detected. When at least 1% of sur-
rogate cells have detectable vector, pattern of vector integra-
tion site should be assessed. In case persistent monoclonality 
or vector integration near or within locus known to have on-
cogenic activity, additional monitoring is recommended. 
TARGETING RETROVIRAL INTEGRATION; MLV 
VS HIV 
  After entering the host cell, a single-stranded retroviral 
RNA genome is released into the cytoplasm and converted 
into a double-stranded DNA by virus-encoded reverse tran-
scriptase. The viral DNA then forms a large nucleoprotein 
structure, termed pre-integration complex, containing pro-
teins necessary for nuclear localization and insertion of viral 
DNA into the host genome. Although the protein compo-
nents and the exact mechanism of action of the complex is 
still not completely understood, it has been demonstrated that 
viral integrase (IN) catalyzes
 the key DNA cutting and join-
ing reactions for inserting viral
 DNA into the host genome 
[48, 49]. 
  Retroviral integration is not a completely random process 
but favors promoters and enhancer regions while lentiviral 
vectors integrate more randomly throughout the entire gene 
[50, 51]. Due to the differences of insertional preferences 
between two vectors, it was considered that HIV based gene 
therapy is safer than MLV based one. However, recent result 
from a gene transfer study of -thalassemia Major and Sickle 
Cell anemia conducted in France suggests a different story 
[52]. Office of Biotechnology Activities of National Insti-
tutes of Health (NIH) published a letter in June, 2009 that a 
relative clonal dominance was detected in a subject with -
thalassemia Major, two years after the treatment. The vector 
used in the study was a self-inactivating (SIN) HIV-1 de-
rived lentivirus which contains the gene for -globin under 
the control of the -globin promoter. Clonal populations 
share an integration site in HMGA2 gene. This incident 
raised a question about whether the use of lentiviral and 
modified SIN retroviral vectors containing insulators can 
decrease the risk of insertional mutagenesis in hematopoietic 
stem cells. 
  There are controversial reports about the function of viral 
proteins including integrase. Swapping the integrase between 
closely related viruses showed a change in the integration 
pattern [53, 54]. However, changing of gag, env, and pol 
genes of MLV with those from subgroup C Feline Leukemia 
Virus (FeLV-C) did not alter the basic integration profile 
[55]. Elucidating the mechanisms of integration and estab-
lishing the database for preferred integration sites could 
permit a better prediction of the integration sites of retroviral 
vectors. This may eventually lead to the development of ret-
roviral vectors capable of integration site selection in the 
host cell chromosome, providing the ultimate solution to the 
problems of insertional mutagenesis.  
  There have been attempts to target retroviral integration 
to pre-selected locations of the host genome by fusing viral 
integrase with sequence-specific DNA binding domains ob-
tained from phage lambda repressor, bacterial LexA, or a 
zinc finger protein zif268 [56-58]. However, these trials 
show only a limited success, as the specificity of integration 
was only partially altered. In a separate experiment, bovine 
leukemia virus (BLV) integrase was used for site-specific 
integration of naked DNA to the pre-integrated integrase 
recognition sequence of mouse genome [59]. Similarly, site-
specific integration of naked DNA into human chromosome 
8 has been attempted with limited success using modified 
phage C-31 integrase [60]. In this study, enhanced sequence 
specificity and increased integrase efficiency was achieved 
through a directed evolution strategy. It is clear that concen-
trated efforts are required in defining the precise mechanism 
of action of the retroviral pre-integration complex and in 
designing modified integrases with sequence-specific inte-
gration capability. The latter may be accomplished either by 
rational modification of the protein or by using the directed Current Advances in Retroviral Gene Therapy  Current Gene Therapy, 2011, Vol. 11, No. 3    221 
evolution approach [61]. One example of rational modifica-
tion is fusing integrase with synthetic zinc finger motifs with 
defined sequence specificities [58, 62, 63]. Directed evolu-
tion utilizes error-prone PCR-driven mutagenesis, recombi-
nation, or DNA shuffling, combined with a high throughput 
screening for the selection of modified proteins with signifi-
cantly improved function. The newly developed integrases 
should also maintain the ability to form a pre-integration 
complex with a high-level of infection capability.  
  Generation of integration deficient lentiviral vectors was 
also reported [64, 65]. The vector showed durable transcrip-
tion of transgenes in certain mitotic cell lineages, but non-
integrated viruses were lost during cell division. 
INSULATORS TO PREVENT POSITIONAL EFFECTS 
AND INSERTIONAL ONCOGENE ACTIVATION  
  Retroviruses are often susceptible to positional effects 
and transcriptional silencing depending on the site of integra-
tion in the chromosome [66]. In order to overcome positional 
silencing effect, chromatin insulators have been used in ret-
roviral vectors. Chromatin insulators are believed to form 
expression boundaries [67, 68] and can block positive and 
negative positional effects at the site of integration when 
they flank a transgene [69-71]. They prevent interferences 
between promoters and enhancers of adjacent genes [72]. As 
an example, when a 1.2 kb chromatin insulator obtained 
from the chicken -globin locus control region hypersensi-
tive site 4 (cHS4) was inserted in the retrovirus 3’ LTR, pro-
tection of the positional effects was observed either from 
transduced cultured cells and from mice transplanted with 
transduced marrow cells [73]. Similarly, cHS4 insulator used 
with gamma-globin expression cassette increased the likeli-
hood of stable gamma-globin expression nearly 10-fold, al-
lowing for the expression at the therapeutic range for treating 
sickle cell anemia and beta thalassemia in mouse bone mar-
row transplantation models [74]. A part of full length cHS4 
(650 bp) was confirmed to work for the practical purpose 
[75]. Insertion of a cHS4 in SIN lentiviral vectors resulted in 
higher and less variable expression of human ß-globin [76, 
77]. 
  Because sequences in the 3’ LTR of retroviral vectors are 
copied to the 5’ LTR during the processing of viral genome 
into the provirus, if an insulator is inserted in the 3’ LTR of 
the recombinant vector, a barrier of insulators will be formed 
surrounding the transgene Fig. (1A). In addition, insulators 
are inserted in the place of the U3 region of the 3’ LTR, 
which is the viral enhancer region. These vectors will be-
come SIN in the proviral form, as there is no viral enhancer 
required to produce replication competent retrovirus. There-
fore, insulator containing retroviral vectors will be less prone 
to silencing of the transgene expression as a result of chro-
mosome positional effect [73], and at the same time, will 
have less chance of causing aberrant induction of host genes 
near the site of incorporation as it has no viral enhancer. 
Boundaries formed by insulators will also prevent the influ-
ence of an internal heterologous enhancer used to drive 
transgene expression on the transcription of nearby host 
genes, although it has yet to be experimentally proven. 
  Although retroviral insertion can cause either a disruption 
or an abnormal activation of host genes, the latter is a pri-
mary concern in terms of oncogenesis. This is because, in 
most cases, retroviral insertion will occur in only one allele 
of the host genome leaving the other locus intact, and inser-
tional disruption of the host gene will become problematic 
only in rare cases where haplo-insufficiency is phenotypi-
cally relevant for oncogenic transformation. Thus, although 
chromatin insulators cannot prevent host gene disruption by 
retroviral insertion, the benefits associated with the use of 
insulators preventing unwanted activation of host genes will 
be rather significant.  
  The efficiency of insulator function is, however, depend-
ent on several factors including topological constraints, cell 
types, and the state of cell differentiation [78, 79]. Also the 
size limitations of retroviral vectors should be considered. A 
265 bp sea urchin insulator termed sns (silencing nucleopro-
tein structure) was found to be effective for insulator func-
tion in human cells, and thus may be useful in retroviral vec-
tors [80, 81]. In a recent report, anti-repressor elements were 
identified by screening a library of human genomic DNA 
fragments between 500 and 2,000 bp, based on their ability 
to relieve LexA-dependent transcription repression [82]. 
These elements can confer high and stable transgene expres-
sion in mammalian cells when they were used to flank the 
transgene, suggesting that they play a similar role as insula-
tors.  
  Scaffold (or matrix) attachment region (SAR) is another 
DNA sequence element believed to play an important role in 
defining boundaries of independent chromatin domains [83, 
84]. SARs bind to the nuclear scaffold or nuclear matrix with 
high affinity and are proposed to form chromosomal loops 
[85]. SARs have been used in retroviral vectors with an en-
hancement of transgene expression in several different cell 
types [86, 87]. A report shows that a high-level transgene 
expression can be achieved from a SIN lentiviral vector con-
taining both the human interferon-beta scaffold attachment 
region and the chicken -globin insulator [88]. The proviral 
form of this vector does not contain HIV-1 U3 region tran-
scriptional regulatory elements and is flanked by the enhan-
cer-blocking -globin insulators. These observations indicate 
that the usage of SARs in addition to insulators could sig-
nificantly improve transgene expression and lower the risk of 
uncontrolled activation of cellular proto-oncogenes at or near 
the site of incorporation. 
  Activation of proto-oncogene may also arise due to the 
retroviral RNA processing. A strong internal splice acceptor 
(SA) is recommended after the splice donor (SD) of retrovi-
ral vector to reduce the positional effects of inserted retrovi-
ral RNA processing on the expression of the transgene as 
well as the disrupted host gene. Combination of a strong SA, 
deleting cryptic SD in the transgene [89], using an improved 
polyadenylation signal [90], the removal of LTR promoter, 
and the insulator will largely prevent the interactions of the 
retroviral splice donor with downstream chromosome se-
quences. 
TRANSCRIPTIONAL TARGETING 
  Transcriptional targeting using cell type-specific promot-
ers and enhancers can be applied either alone or in combina-
tion with targeted transduction to minimize the expression of 

























Fig. (1). Designs of the improved retroviral vectors. (A) Insulator located in U3 of 3’LTR is copied to 5’LTR in target cell. Insulators located 
in the both ends of vector DNA blocks the cross activation between retroviral DNA and the chromosomal DNA. (B) Due to the duplication of 
U3-deleted LTR of the SIN vector in target cell, the proviral form does not contain viral enhancer any more, and thus require an internal pro-
moter for the expression of the transgene. Arrows show the transcription start. P, internal promoter; U3, deletion of U3 sequence. (C) Com-
parison of splicing in conventional and split-intron vectors. Arrows show transcripts from the vector DNA. SD, Splice Donor site; SA, Splice 
Acceptor site. 
Table 1.  Retroviral Vectors for Targeted Infection 
Modification Target  Cell  References 
EGF-MMP cleavable linker chimeric env  Cancer invasion, angiogenesis, inflammation  [16, 17, 20] 
IL-2 chimeric env  IL-2 R  [27] 
EGF chimeric env  EGFR  [15] 
SCF-Factor Xa chimeric env  Stem cell (Kit)  [19] 
vWF (collagen binding) chimeric env  Cancer (collagen expressing); vascular lesion  [23, 24] 
Single-chain variable fragmented antibody (scFv) for EGFRvIII  Cancer (brain, breast, lung, ovary)  [29] 
scFv for HMWMAA  Cancer  [22] 
scFv from phage display  T cell  [28] 
scFv for Carcino embryonic antigen (CEA)  Cancer  [30] 
Receptor pseudotyping (CD4 and CXCR4)  HIV-1 infected cell  [31, 32] 
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Table 2.  Cell Type-Specific Promoters and Enhancers for Transcriptional Targeting in Retroviral Gene Therapy 
Promoter Target  Cell/Tissue  Transgene  References 
PEPCK promoter  Hepatocyte  Neo, bovine growth hormone  [99] 
hAAT promoter  Hepatocyte  Alpha I antitrypsin  [100] 
MMTV-LTR Mammary  gland  TNF- [92] 
MCK promoter  Muscle  -galactosidase, dystrophin minigene  [101] 
AFP promoter  Cancer: Hepatocellular carcinomas  HSV-tk, VZV-tk  [102] 
Tyrosine promoter  Cancer: Melanomas  HSV-tk, IL-2  [91] 
Col1a1 promoter  Bone  -geo (-gal, neo fusion)  [103] 
HSP70 promoter  Cancer  Dominant negative IGF-IR  [104] 
WAP promoter  Cancer: Mammary  -galactosidase [105] 
ppET1 promoter  Cancer: Endothelium  -galactosidase [106] 
AFP enhancer; PGK promoter  Cancer: Hepatocellular carcinomas  HSV-tk  [96] 
HRE, PGK-1 enhancer; E-selectin, KDR promoter  Cancer: Endothelium  TNF-, luciferase  [95] 
HRE enhancer; AFP promoter  Cancer: Hepatocellular carcinomas  HSV-tk, luciferase  [107] 
Rat alpha-fetoprotein  Human hepatocarcinoma cell  HSV-tk, luciferase  [97] 
HS2 of erythroid-specific GATA-1 gene; HIV-1 
promoter 
Mature erythroblasts  GFP  [98] 
 
potential side effects. Table 2 summarizes examples of cell 
type-specific promoters and enhancers used for transcrip-
tional targeting in retroviral gene therapy. Promoters of on-
cogenes overexpressed in the tumor cells can be the targets 
for tumor specific promoters (e.g. c-erbB2 and c-myc). Ty-
rosinase promoter was used for the expression of HSV-tk or 
IL-2 for the treatment of malignant melanomas [91]. Ty-
rosinase is rate-limiting enzyme for melanin production, 
which is highly expressed in melanomas. In addition to cell 
type-specific promoters, inducible or regulatable expression 
systems can also be used for safety and efficacy. In the case 
for mammary tumor and prostate cancer, the growth of tu-
mor is hormone dependent. Therefore, using a combined 
steroid hormone-responsive and cell type specific promoters 
is an attractive approach for retroviral gene therapy [92]. 
Additionally, genes that are induced by cancer therapies such 
as gamma-irradiation or chemotherapy can also be the tar-
gets for the regulatory elements [93, 94].  
  Although a number of cell type specific promoters were 
tested in many trials, the overall efficiency of transcription 
achieved from cell type specific promoters is relatively weak 
compared to viral promoters generally used. In a report, hy-
poxic and cytokine-inducible enhancers, both of which are 
active in some tumor environments, are combined with endo-
thelial cell-specific E-selectin and VEGF receptor 2 promot-
ers [95] to achieve a maximum possible tumor endothelium-
specific transcription. In another report, human -fetoprotein 
(AFP) enhancer was combined with a housekeeping gene 
phosphoglycerate kinase-1 (PGK-1) promoter, to augment 
the activity of the weak tumor-selective AFP promoter [96].  
  Rat alpha-fetoprotein promoter was used as a cell type-
specific promoter for a lentivirally transduced expression in 
human hepatocarcinoma cells [97]. Replacement of U3 re-
gion of the lentiviral LTR with an upstream enhancer (HS2) 
of the erythroid-specific GATA-1 gene and HIV-1 promoter 
showed a high level of transgene expression specifically in 
mature erythroblasts [98].  
  In many cases, the size constraints of retroviral vector 
limit the use of enhancers, which are generally long in size. 
Therefore, construction of minimum enhancer/promoter cas-
settes with strategic combinations of different sequence ele-
ments will be required to facilitate the efficacy of gene ther-
apy trials.  
COEXPRESSION OF A SUICIDAL GENE 
  Herpes simplex virus thymidine kinase (HSV-tk) has 
been used for selective destruction of cells in several differ-
ent settings. When anti-viral prodrug nucleobase analogue 
ganciclovir (GCV) is applied to HSV-tk expressing cells, 
GCV is efficiently converted into monophosphate form by 
HSV-tk, and then into cytotoxic triphosphate derivatives by 
cellular kinases. Actively dividing cells will be killed as they 
incorporate the nucleotide derivatives into their genome. In 
allogeneic bone marrow transplantation (BMT), donor T 
cells are able to mediate anti-leukemic effects but they can 
also induce graft-vs-host disease (GvHD), which is often 
fatal. In an attempt to reduce GvHD while maintaining anti-
leukemic effect, scientists have retrovirally transduced HSV-
tk to donor T-cells before being used in animal myeloabla-
tive BMT trials [108]. At first, the donor T-cells helped to 224    Current Gene Therapy, 2011, Vol. 11, No. 3  Yi et al. 
eliminate residual malignant leukemic cells, but when signs 
of GvHD development were noticed, proliferating donor T-
cells were rapidly destroyed by treating the animals with 
ganciclovir. When this strategy was used in a human trial, 
three out of eight patients treated with donor lymphocytes 
transduced with HSV-TK gene could be effectively con-
trolled by ganciclovir-induced elimination of the transduced 
cells when they developed GvHD 12 months after transduc-
tion [109]. 
  Similarly, retroviral vectors can be designed to co-
express HSV-tk suicide gene to be used as a safety switch, in 
addition to a therapeutic gene. If abnormal growth of trans-
duced cells is observed such as the cases in the X-SCID, 
treatment with ganciclovir can eliminate all the transduced 
cells theoretically. However, constitutive expression of 
HSV-tk can also induce the death of neighboring uninfected 
cells by the bystander effects when ganciclovir is adminis-
tered. In order to minimize unwanted side effects due to by-
stander effects, the use of cell type-specific or inducible 
promoter for the expression of HSV-tk or the use of other 
pro-apoptotic genes with a minimum bystander effect may 
be advantageous. As an example, lentivirally transduced 
expression unit containing the rat alpha-fetoprotein promoter 
was used to restrict the HSV-tk induced GCV sensitivity to 
human hepatocarcinoma cells [97].  
  On the other hand, retroviral vectors expressing HSV-tk 
have been used in antitumor treatment trials [110-112]. In 
this case, maximum “bystander effect” is required to kill 
neighboring uninfected cells as well as infected cells. The 
results of tumor treatment with HSV-tk expressing retroviral 
vectors were, however, not fully successful due to low infec-
tion efficiency and weak bystander effects.  
  One potential obstacle for co-expressing HSV-tk suicide 
gene as a safety switch in addition to the therapeutic gene 
however, is the limited insert size constraint of the retroviral 
vector. In cell-based ex-vivo gene therapy using the clonally-
derived cells, selection of single clones, transduced with two 
separate retroviral vectors harboring the HSV-tk gene and 
the therapeutic gene in each vector, could be a solution for 
the problem of size restriction.  
AVOIDING REPLICATION COMPETENT RETRO-
VIRUS (RCR) 
  Generation of RCR remains as a potential safety issue in 
retroviral gene therapy. Retroviral vectors transfected into a 
packaging cell line can produce RCR by recombination 
processes between homologous sequences of the retroviral 
vector DNA and the gag, pol, and env coding sequences in 
the packaging systems. In order to lower the chances for 
recombination, both minimizing the homologous sequences 
and physically separating genes for gag, pol and env into two 
different expression cassettes, have become standard prac-
tices. However, residual gag, pol, and env coding sequences 
are frequently included in these vectors in an attempt to in-
crease transduction efficiency and viral titer. Therefore, re-
maining part of gag, pol, and env gene is raising a concern 
for RCR generation. There is a report that a complete re-
moval of residual coding sequences for gag, pol, and  env 
genes did not show any detrimental effect on viral transduc-
tion efficiency, and it also reduced the chance of RCR gen-
eration [113]. The same concept was also applied to lentivi-
ral vectors. To avoid the production of replication competent 
lentivirus (RCL), the components required for the production 
of lentivirus were divided into at least three parts: vector 
plasmid which contains the gene of interest and the minimal 
cis-acting element of HIV; packaging plasmid which has all 
HIV viral genes except the env gene; envelope proteins 
which were provided from a plasmid containing the envelope 
gene via co-transfection. Typically, the Glycoprotein from 
vesicular stomatitis virus (VSV-G) is used as an envelope 
gene [114]. One of the safety concerns specific to HIV virus 
is the recombination between vector sequences and endoge-
nous HIV sequences in HIV positive patients. In spite of the 
large deletion of endogenous retroviral sequences, the possi-
bility of recombination and mobilization cannot be over-
looked. Stable lentivirus producer cell line has been tried due 
to the higher probability of recombination during the packag-
ing process through transient transfection is much higher 
than that of the stable producer cell lines [115, 116]. Due to 
the concerns of using HIV in humans, researchers are devel-
oping non-human lentiviral vector systems. Simian immu-
nodeficiency virus (SIV), Feline immunodeficiency virus 
(FIV), and Equine immunodeficiency virus (EIAV) are some 
of them [117-119]. However, the safety features of non-
primate lentiviruses in humans have yet to be determined 
[120]. 
  SIN retroviral vector was developed by introducing a 
deletion in the U3 region of the 3’ LTR which contains all 
the enhancer and promoter activities of the viral vector Fig. 
(1B) [121]. No active viral particle is arising from SIN vec-
tors, because the 5’LTR carrying the same deletion in the 
chromosome is not capable of inducing transcription for the 
production of packagable RNAs. An additional advantage of 
the SIN vector is the minimal chance of LTR-mediated inser-
tional activation of proto-oncogene near the site of insertion. 
SIN vector approach has been tested more extensively in 
lentiviruses [122]. Although SIN vector was considered as an 
ideal vector, a SIN vector mobilization was detected with a 
very low level [116]. Additionally, one of the drawbacks of 
SIN retroviral vectors is the low transcriptional activity of 
the internal promoter compared to the viral LTR in a number 
of different cell types. Improvements in the design of the 
internal promoter/enhancer are required to overcome this 
obstacle.  
  Split-intron retroviral vector has been shown to enhance 
expression of an inserted gene and safety was improved [90]. 
A strong synthetic splice donor (SD) site and a splice accep-
tor (SA) site were inserted between U3 and R of the 3’ LTR 
and downstream of the packaging signal, respectively. Dur-
ing the reverse transcription process, the strong synthetic 
splice donor site introduced in the 3’ LTR is copied into 
5’LTR, and theoretically all the transcripts made in the 
transduced cells are spliced and the packaging signal is re-
moved Fig. (1C). Therefore, the possibility of producing 
RCR is greatly reduced.  
  Finally, activation of proto-oncogene may arise due to 
aberrant retroviral RNA processing. A strong internal SA is 
recommended after SD site of retroviral vector to prevent a 
generation of aberrant read through transcripts containing 
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Combination of strong SA, deleting cryptic SD in the trans-
gene [89], an improved polyadenylation signal [123], re-
moval of LTR promoter, and the presence of an insulator 
will largely prevent the interactions of the retroviral splice 
donor with downstream chromosome sequences. 
CONCLUDING REMARKS 
  Applications of gene therapy protocols have been con-
tinuously expanded to wide variety of acquired and inherited 
diseases, such as cancer, SCID, and other life threatening 
diseases. Retroviral gene therapy approaches for the treat-
ment of these diseases have to address safety issues. Tar-
geted infection, local delivery, targeted retroviral insertion, 
insulators, transcriptional targeting, co-transduction with a 
suicidal gene, and SIN vectors were suggested as possible 
solutions for the risks of retroviral gene therapy. Some of 
these precautions can also be applied to gene therapy proto-
cols using other viral and non-viral vector systems. One ma-
jor immediate concern in terms of retroviral gene therapy, as 
revealed by the X-SCID case, is insertional oncogenesis. 
Several approaches to decrease the possibility of insertional 
oncogenesis were considered in depth. In addition to the 
widely used retroviral systems that were discussed above, 
foamy viruses may be used as a safe and efficient means of 
targeting non-dividing cells [124, 125]. Foamy viruses are 
known to have a broad host range, without causing any dis-
ease and persist in infected humans [126-128]. In the case of 
ex vivo cell-based gene therapy, transduced cells could be 
pre-screened to select for clones with the insertion of the 
transgene only at a desirable site of the chromosome, which 
can minimize the chances for insertional oncogenesis. Or-
thopedic indication is one of the most promising areas of 
gene therapy in spite of the non-lethal conditions [37, 129-
135].  
  The incident from a gene transfer study of -thalassemia 
Major in France showed us that there is no guaranteed way 
to safe gene therapy. Pursuing prudent designing of vectors 
and monitoring adverse effects in patients are proper direc-
tions. Additionally, selection of patient specific method is 
recommended for each patient based on the risk versus bene-
fit. 
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